NVCR Stock Analysis: Buy, Sell, or Hold?
NVCR - NovoCure Limited Ordinary Shares
$17.10
-0.67 (-3.77%)
▼
5d:
+0.88%
30d:
-14.46%
90d:
-4.47%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 21, 2026 at $17.10 · last confirmed Aug 21, 2026
Strength: 4.2/10
Get Alerted When NVCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NVCR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NVCR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NVCR is currently trading at $17.10, which is considered extended relative to its 30-day fair value range of $15.45 to $17.65.
Technical Outlook: Technically, NVCR is in a strong downtrend. Immediate support is located at $16.27, while resistance sits at $18.61. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: NVCR scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.14 (+58.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVCR is in a strong downtrend. Immediate support is located at $16.27, while resistance sits at $18.61. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: NVCR scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.14 (+58.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.45 -
$17.65
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
Protect Your Profits
Holding NVCR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 58.7% below Wall St target ($27.14)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$15.45 -
$17.65
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.27
Resistance Level
$18.61
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.95
Wall Street Target
$27.14
(+58.7%)
Revenue Growth (YoY)
15.6%
Earnings Growth (YoY)
-6.0%
Profit Margin
-21.2%
Share & Embed Analysis
Last updated: August 22, 2026 12:41 PM ET
Data refreshes hourly during market hours. Next update: 1:41 PM
Data refreshes hourly during market hours. Next update: 1:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Mukund Paravasthu
SELL
43246 shares
2026-03-05
Christoph Brackmann
SELL
6412 shares
2026-03-04
Frank X Leonard
SELL
5607 shares
2026-03-04
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
Advanced NVCR Option Strategies
Professional options setups generated by AI based on today's NVCR price and gamma walls.
